Background Severe cases of coronavirus disease 2019(COVID-19)among pediatric patients are more common in children less than 1 year of age.Our aim is to address the underlying role of immunity and inflammation conditio...Background Severe cases of coronavirus disease 2019(COVID-19)among pediatric patients are more common in children less than 1 year of age.Our aim is to address the underlying role of immunity and inflammation conditions among different age groups of pediatric patients.Methods We recruited pediatric patients confirmed of moderate COVID-19 symptoms,admitted to Wuhan Children's Hospital from January 28th to April 1st in 2020.Patients were divided into four age groups(≤1,1–6,7–10,and 11–15 years).Demographic information,clinical characteristics,laboratory results of lymphocyte subsets test,immune and inflammation related markers were all evaluated.Results Analysis included 217/241(90.0%)of patients with moderate clinical stage disease.Average recovery time of children more than 6 years old was significantly shorter than of children younger than 6 years(P=0.001).Reduced neutrophils and increased lymphocytes were significantly most observed among patients under 1 year old(P<0.01).CD19+B cells were the only significantly elevated immune cells,especially among patients under 1 year old(cell proportion:n=12,30.0%,P<0.001;cell count:n=13,32.5%,P<0.001).While,low levels of immune related makers,such as immunoglobulin(Ig)G(P<0.001),IgA(P<0.001),IgM(P<0.001)and serum complement C3c(P<0.001),were also mostly found among patients under 1 year old,together with elevated levels of inflammation related markers,such as tumor necrosis factor γ (P=0.007),interleukin(IL)-10(P=0.011),IL-6(P=0.008),lactate dehydrogenase(P<0.001),and procalcitonin(P=0.007).Conclusion The higher rate of severe cases and long course of COVID-19 among children under 1 year old may be due to the lower production of antibodies and serum complements of in this age group.展开更多
文摘Background Severe cases of coronavirus disease 2019(COVID-19)among pediatric patients are more common in children less than 1 year of age.Our aim is to address the underlying role of immunity and inflammation conditions among different age groups of pediatric patients.Methods We recruited pediatric patients confirmed of moderate COVID-19 symptoms,admitted to Wuhan Children's Hospital from January 28th to April 1st in 2020.Patients were divided into four age groups(≤1,1–6,7–10,and 11–15 years).Demographic information,clinical characteristics,laboratory results of lymphocyte subsets test,immune and inflammation related markers were all evaluated.Results Analysis included 217/241(90.0%)of patients with moderate clinical stage disease.Average recovery time of children more than 6 years old was significantly shorter than of children younger than 6 years(P=0.001).Reduced neutrophils and increased lymphocytes were significantly most observed among patients under 1 year old(P<0.01).CD19+B cells were the only significantly elevated immune cells,especially among patients under 1 year old(cell proportion:n=12,30.0%,P<0.001;cell count:n=13,32.5%,P<0.001).While,low levels of immune related makers,such as immunoglobulin(Ig)G(P<0.001),IgA(P<0.001),IgM(P<0.001)and serum complement C3c(P<0.001),were also mostly found among patients under 1 year old,together with elevated levels of inflammation related markers,such as tumor necrosis factor γ (P=0.007),interleukin(IL)-10(P=0.011),IL-6(P=0.008),lactate dehydrogenase(P<0.001),and procalcitonin(P=0.007).Conclusion The higher rate of severe cases and long course of COVID-19 among children under 1 year old may be due to the lower production of antibodies and serum complements of in this age group.
